Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Biopharmaceutical company Arena Pharmaceuticals (NASDAQ: ARNA) has announced it is advancing its etrasimod eczema treatment into Phase 3 trials despite mixed results.
Arena revealed that the study failed to meet its primary endpoint of Eczema Area and Severity Index (EASI) change from the baseline at week 12 compared to the placebo.
The San Diego-based company also said that between weeks 4-8, the trial was impacted by unwarranted dose interruption that was not related to drug safety.
However, about a third of participants in the 2 mg estrasimod group achieved clear or almost clear skin, while there were no safety concerns.
Despite the mixed results, the company were happy with the trial and have decided to initiate a Phase 3 program.
“Today is an important day for Arena as we achieved our key objectives for the ADVISE trial which were to evaluate safety and efficacy of etrasimod in a dermatologic population, and to inform dose and design decisions for a pivotal Phase 3 program,” stated Chris Cabell, Executive Vice President, at Arena.
“We believe the clinical benefits of etrasimod in this trial were impressive, especially given the challenges of conducting a Phase 2 trial with a novel MOA in atopic dermatitis,” Cabell continued.
Investors haven't reacted well to the news with Arena's share price plummeting premarket and falling further after the open. Its shares are trading at $66.72, down 23.68% at the time of this publication.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .